A Phase II Study of Palbociclib for Recurrent or Refractory Advanced Thymic Epithelial Tumor
Status:
Unknown status
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
This is a phase II single center, open-label, single arm study of palbociclib treatment in
patients with recurrent or metastatic advanced TETs after failure of one or more cytotoxic
chemotherapy regimens. Patients will receive oral palbociclib 125mg daily for 21days followed
by a 7-day break. Cycle will be repeated every 28 days.